low-grade developmental and epilepsy-associated brain tumors（ LEAT） are the second most common cause of focal epilepsy in adolescents. These tumors present primarily with epileptic seizures and carry a favorable prognosis. Common types include ganglioglioma（ GG） and dysembryoplastic neuroepithelial tumor （DNT）. The 2021 fifth edition of the WHO Classification of Tumors of the Central Nervous System（ CNS WHO 5th） has introduced molecular typing， which aids in the diagnosis and classification of LEAT. LEAT molecular types include tumors predominantly driven by BRAF V600E mutation， fibroblast growth factor receptor 1（ FGFR1） mutation， and MYB alterations. Surgical treatment is the primary method for this condition. Most patients experience relief from epileptic symptoms after surgery. However， for patients with persistent seizures， longterm use of antiepileptic drugs is recommended. At present， the impact of LEAT molecular typing on treatment and prognosis requires further investigation. This paper provides a review of LEAT based on CNS WHO 5th， aiming to provide reference for the diagnosis and treatment of LEAT